【摘要】 目的:研究抗乙肝病毒药物拉米夫定治疗慢性乙型肝炎的疗效。方法:门诊慢性乙型肝炎患者216例口服拉米夫定,1次/d100mg/次,疗程1年。定期检测血常规、肝功能及病毒学指标等。结果:拉米夫定治疗慢性乙型肝炎疗程1年,有71.8%的HBV-DNA转阴,68.1%肝功能保持正常;治疗前HBV-DNA不同水平组间的HBV-DNA转阴率、HBeAg转阴率和HBeAg/抗HBe血清转换率无显著性差异(P>0.05);而治疗前ALT不同水平组间有极显著性差异(P<0.01);综合疗效评价,完全应答率为22.7%,部分应答率为66.7%;无明显不良反应。结论:拉米夫定能有效抑制HBV-DNA的复制,使ALT恢复正常,降低慢性乙型肝炎的复发率,耐受性良好,安全性较高。更多还原

【Abstract】 Objective:To evaluate the clinical efficacy of lamivudine in the treatment of chronic hepatitis B.Methods:The patients with chronic hepatitis B received 100 mg lamivudine orally daily for one year.HBV-DNA, ACT and HBeAg seroconversion in serum were examined before,during and after the treatment.Results:71.8%patients were conversed to HBV-DNA negative.ACT values of 68.1%patients were normal.The rates of HBeAg seroconversion and HBV-DNA negative in several groups were no difference(P > 0.05).The effective rate of all patients with chronic hepatitis B was 22.7%.Conclusion:Lamivudine resulted in the clearance of HBV-DNA and prompted ACT values to normal.It appeared to be a useful drug in the treatment of chronic hepatitis B.更多还原